DexCom, Inc. (DXCM) is a growth stock being keenly observed due to successful performance. Its manageable debt and stock retention are points in its favor. However, not all is smooth sailing as it recorded underperformance, reduction of jobs in California and share sellouts by EVP Michael Jon Brown. Despite Q4 earnings miss, revenues were above estimates. It sees potential from its G6 and G7 CGM Systems, which combines with AID in Netherlands and is now Apple Watch compatible. An upcoming Q2 2024 Earnings Release is scheduled for July 25, 2024. Constant earnings surprise and solid growth stock credentials point to a promising future. Several institutional investors like Wall Street, AMF Tjanstepension AB and Wealthcare Advisory Partners LLc have bought stakes in DXCM. It also continues to innovate with products like Stelo Glucose Biosensor and has regulatory approval to boot. Reports show robust revenues and operating income, and it has outpaced many medical stocks this year. Other encouraging signs include its positive ROEs, SWOT analysis and Q1 earnings that outperformed analyst expectations. The stock also seems to promise better returns than the 3M stock. However, there are slight concerns over insider selling and potential competition. Overall, DexCom's prospects seem largely positive.
Dexcom DXCM News Analytics from Thu, 26 Oct 2023 07:00:00 GMT to Sat, 29 Jun 2024 12:03:12 GMT -
Rating 6
- Innovation 6
- Information 7
- Rumor 2
